Filing Details

 

CUSIP No. 003939W 109

SCHEDULE 13G

Page 2 of 6 Pages

1.NAMES OF REPORTING PERSONS 

Michael Parker  

 

2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) 

 

(a)    x

(b)   ☐  

 

3.SEC USE ONLY  

 

4.CITIZENSHIP OR PLACE OF ORGANIZATION 

 

United States  

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

5.SOLE VOTING POWER 

 

14,244,291 shares of Common Stock  

 

6.SHARED VOTING POWER 

 

N/A  

 

7.SOLE DISPOSITIVE POWER 

 

14,244,291 shares of Common Stock

   

8.SHARED DISPOSITIVE POWER 

 

N/A  

 

9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

 

14,244,291 shares of Common Stock (see Item 4)

 

10.CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)  

 

x

 

11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 

 

7.58% (see Item 4)  

 

12.TYPE OF REPORTING PERSON (see instructions) 

 

IN

 

CUSIP No. 003939W 109

SCHEDULE 13G

Page 3 of 6 Pages

 

Item 1.

 

(a)Name of Issuer 

Arch Therapeutics, Inc.

 

(b)Address of Issuer's Principal Executive Offices 

235 Walnut Street, Suite 6, Framingham, MA  01702  

Item 2.

 

(a)Name of Person Filing 

Michael Parker

 

(b)Address of the Principal Office or, if none, residence 

1928 East Highland Avenue, Suite F104-558, Phoenix, Arizona 85016

 

(c)Citizenship 

United States

 

(d)Title of Class of Securities 

Common Stock, par value $0.001 per share

 

(e)CUSIP Number 

003939W 109

 

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). 

 

(b)Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). 

 

(c)Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). 

 

(d)Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). 

 

(e)An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 

 

(f)An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 

 

(g)A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); 

 

(h)A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

 

(i)A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 

 

(j)Group, in accordance with §240.13d-1(b)(1)(ii)(J). 

 

CUSIP No. 003939W 109

SCHEDULE 13G

Page 4 of 6 Pages

 

Item 4.  Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a) Amount beneficially owned:  14,244,291 shares of Common Stock *  

 

(b)Percent of class:  7.58% ** 

 

(c)Number of shares as to which the person has:   

 

(i)Sole power to vote or to direct the vote 14,244,291 shares of Common Stock 

 

(ii)Shared power to vote or to direct the vote 0. 

 

(iii)Sole power to dispose or to direct the disposition of 14,244,291 shares of Common Stock *  

 

(iv)Shared power to dispose or to direct the disposition of 0. 

 

* Includes 1,380,891 shares of Common Stock owned individually by Michael Parker; 7,863,400 shares of Common Stock owned individually by Ana B Parker, spouse of Michael Parker; and 5,000,000 shares of Common Stock owned through Tungsten III LLC, of which Michael Parker is the sole manager.  Does not include any of the 4,500,000 shares of Common Stock that may be acquired upon the exercise of Series D Warrants (which expire on June 30, 2020), any of the 1,583,333 shares of Common Stock that may be acquired upon the exercise of Series E Warrants (which expire May 26, 2021), any of the 600,000 shares of Common Stock that may be acquired upon the exercise of Series G Warrants (which expire July 2, 2023), any of the 1,230,769 shares of Common Stock that may be acquired upon the exercise of Series H Warrants (which expire May 14, 2024), any of the 3,428,571 shares of Common Stock that may be acquired upon the exercise of Series I Warrants (which expire October 18, 2024), as all such warrants cannot be exercised until such time as the holder would not beneficially own, after such exercise, more than 4.9% of the outstanding shares of Common Stock (the “Blocker”); provided, however, that the holder may waive such ownership limitation, in which case such waiver will become effective sixty-one (61) days after the holder's delivery of such waiver notice.  As of the date of this Schedule 13G, such limitation has been waived. 

 

**Based on the most recently reported figure for outstanding shares contained in the Company's 10-K filed on November 19, 2019, which indicated that the total number of outstanding shares of Common Stock as of November 18, 2019 was 187,862,947.   

 

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

 

CUSIP No. 003939W 109

SCHEDULE 13G

Page 5 of 6 Pages

 

Item 5.  Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following    ☐.

 

Instruction. Dissolution of a group requires a response to this item.

 

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable

 

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable

 

Item 8.  Identification and Classification of Members of the Group.

 

Not applicable

 

Item 9.  Notice of Dissolution of Group.

 

Not applicable

 

Item 10.  Certification.

 

(a)The following certification shall be included if the statement is filed pursuant to §240.13d-1(b): 

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

 

(b)The following certification shall be included if the statement is filed pursuant to §240.13d-1(c): 

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.          

 

CUSIP No. 003939W 109

SCHEDULE 13G

Page 6 of 6 Pages

 

SIGNATURE 

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated:  January 23, 2020

 

/s /Michael A. Parker

Signature

 

Michael A. Parker

Name/Title

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, Provided, however, That a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.